Apellis Pharmaceuticals Inc (APLS)
38.07
-1.66
(-4.18%)
USD |
NASDAQ |
Jun 21, 16:00
38.09
+0.02
(+0.05%)
After-Hours: 20:00
Apellis Pharmaceuticals Accounts Receivable (Quarterly): 267.84M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 267.84M |
| December 31, 2023 | 206.44M |
| September 30, 2023 | 169.26M |
| June 30, 2023 | 110.91M |
| March 31, 2023 | 31.50M |
| December 31, 2022 | 7.727M |
| September 30, 2022 | 8.091M |
| Date | Value |
|---|---|
| June 30, 2022 | 7.518M |
| March 31, 2022 | 6.33M |
| December 31, 2021 | 10.10M |
| September 30, 2021 | 3.522M |
| June 30, 2021 | 0.719M |
| March 31, 2021 | |
| December 31, 2020 | 0.00 |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
--
Minimum
Dec 2020
267.84M
Maximum
Mar 2024
63.84M
Average
8.091M
Median
Sep 2022
Accounts Receivable (Quarterly) Benchmarks
| Blueprint Medicines Corp | 60.05M |
| Alnylam Pharmaceuticals Inc | 321.38M |
| Cytokinetics Inc | 0.834M |
| Amicus Therapeutics Inc | 76.43M |
| Insmed Inc | 37.16M |